## PEER-REVIEW REPORT

Name of journal: World Journal of Diabetes
Manuscript NO: 89543
Title: Ne-carboxymethyl-lysine and inflammatory cytokines, markers and mediators of coronary artery disease progression in diabetes

Provenance and peer review: Invited Manuscript; Externally peer reviewed
Peer-review model: Single blind
Reviewer's code: 04122784
Position: Editorial Board
Academic degree: MD, PhD
Professional title: Doctor, Research Assistant Professor
Reviewer's Country/Territory: China
Author's Country/Territory: Spain
Manuscript submission date: 2023-11-05
Reviewer chosen by: Yu-Lu Chen
Reviewer accepted review: 2023-11-28 06:58
Reviewer performed review: 2023-11-28 07:42
Review time: 1 Hour

| Scientific quality | [ ] Grade A: Excellent [ ] Grade B: Very good [ Y] Grade C: Good <br> [ ] Grade D: Fair [ ] Grade E: Do not publish |
| :---: | :---: |
| Novelty of this manuscript | [ ] Grade A: Excellent [ Y$]$ Grade B: Good [ ] Grade C: Fair [ ] Grade D: No novelty |
| Creativity or innovation of this manuscript | [ ] Grade A: Excellent [ Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No creativity or innovation |

# 15 <br> Baishideng Publishing <br> Jaishideng ${ }^{\circledR}$ Group 

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: office@baishideng.com
https://www.wjgnet.com

| Scientific significance of the conclusion in this manuscript | [ ] Grade A: Excellent [ Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No scientific significance |
| :---: | :---: |
| Language quality | [ ] Grade A: Priority publishing [ Y ] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection |
| Conclusion | [ ] Accept (High priority) [ Y] Accept (General priority) <br> [ ] Minor revision [ ] Major revision [ ] Rejection |
| Re-review | [ Y] Yes [ ] No |
| Peer-reviewer statements | Peer-Review: [ Y] Anonymous [ ] Onymous |
|  | Conflicts-of-Interest: [ ] Yes [ Y] No |

## SPECIFIC COMMENTS TO AUTHORS

The manuscript is well-written. This study contributes to the knowledge of biomarkers and therapeutic targets for diabetic patients and identification of the phenotype with higher risk for CAD events. This is a new avenue of personalized medicine.

